Treatment of coagulation disease by administration of recombinant VWF

US9272021B2 · kind B2 · utility

Assignee

• Baxalta Incorporated · CH

Inventors

• Friedrich Scheiflinger · Wien, AT
• Peter Turecek · Klosterneuburg, AT
• Bruce Ewenstein · Brookline, US
• Wing Yen Wong · Simi Valley, US
• Tobias M. Suiter · Wien, AT

Key dates

• Filing date: Jun 11, 2012
• Grant date: Mar 1, 2016
• Expiry date: Sep 16, 2032

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P43/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention provides methods of treating coagulation disease, including hemophilia and von Willebrand disease by administering recombinant von Willebrand Factor alone or in combination with Factor VIII.